Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
GAITHERSBURG, Md. , Jan. 08, 2026 (GLOBE NEWSWIRE) — Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of...
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia , Jan. 08, 2026 (GLOBE NEWSWIRE) — Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide...
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
GAITHERSBURG, Md. , Jan. 07, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa , president and chief executive officer, will provide a company...
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
GAITHERSBURG, Md. , Dec. 12, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics...
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
GAITHERSBURG, Md. , Nov. 18, 2025 (GLOBE NEWSWIRE) — Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN...
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
GAITHERSBURG, Md. , Nov. 12, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective...
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
Third Quarter 2025 Total Revenues of $231.1 million , above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025...
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond...
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
GAITHERSBURG, Md. , Oct. 08, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
GAITHERSBURG, Md. , Sept. 24, 2025 (GLOBE NEWSWIRE) — In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent...
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
GAITHERSBURG, Md. , Sept. 19, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a...
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
GAITHERSBURG, Md. , Sept. 15, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical...